 CAMBRIDGE, Mass.--BUSINESS WIRE--- VBIV--VBI Vaccines Inc. Nasdaq: VBIV VBI, a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that results from a Phase 4 study of VBIs prophylactic 3-antigen hepatitis B virus HBV vaccine in younger adults were published in Vaccine, a journal publication from Elsevier. The study was designed to evaluate the immunogenicity of VBIs 3-antigen HBV vaccine in support of the qual 